Coursera Flash Sale
40% Off Coursera Plus for 3 Months!
Grab it
Learn about the analytical performance characteristics of TruSightâ„¢ Oncology 500 ctDNA version 2, an improved next-generation sequencing-based liquid biopsy assay for comprehensive genomic profiling of solid tumors. Discover how this research-use-only NGS assay utilizes the same gene panel as the original TSO 500 ctDNA while offering significant workflow improvements including reduced circulating free DNA input requirements, decreased total turnaround time, and minimized hands-on time. Explore the technical specifications and performance metrics that enable delivery of key biomarker data from the TSO 500 gene panel, positioning liquid biopsy as an emerging standard of care in oncology. Gain insights from Illumina's Director of Assay Development Jennifer S. LoCoco, PhD, who specializes in designing and optimizing library preparation methods for enriching oncology-relevant variants in various biopsy types including FFPE and cfDNA samples for next-generation sequencing analysis.
